528 related articles for article (PubMed ID: 26669511)
1. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
Cai H; Zhang Y; Han TK; Everett RS; Thakker DR
Int J Cancer; 2016 May; 138(9):2281-92. PubMed ID: 26669511
[TBL] [Abstract][Full Text] [Related]
2. Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours.
Cai H; Everett RS; Thakker DR
Br J Pharmacol; 2019 Aug; 176(15):2724-2735. PubMed ID: 31032880
[TBL] [Abstract][Full Text] [Related]
3. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
4. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
5. Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.
Wang Y; Wei J; Li L; Fan C; Sun Y
Oncol Res; 2014; 22(4):193-201. PubMed ID: 26351208
[TBL] [Abstract][Full Text] [Related]
6. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
[TBL] [Abstract][Full Text] [Related]
7. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
8. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
9. Palmitate activates mTOR/p70S6K through AMPK inhibition and hypophosphorylation of raptor in skeletal muscle cells: Reversal by oleate is similar to metformin.
Kwon B; Querfurth HW
Biochimie; 2015 Nov; 118():141-50. PubMed ID: 26344902
[TBL] [Abstract][Full Text] [Related]
10. Anti-Tumor Activity of Yuanhuacine by Regulating AMPK/mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung Cancer Cells.
Kang JI; Hong JY; Lee HJ; Bae SY; Jung C; Park HJ; Lee SK
PLoS One; 2015; 10(12):e0144368. PubMed ID: 26656173
[TBL] [Abstract][Full Text] [Related]
11. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway.
Li B; Takeda T; Tsuiji K; Kondo A; Kitamura M; Wong TF; Yaegashi N
Gynecol Endocrinol; 2013 Jan; 29(1):87-90. PubMed ID: 22835064
[TBL] [Abstract][Full Text] [Related]
12. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
[TBL] [Abstract][Full Text] [Related]
13. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
Zakikhani M; Blouin MJ; Piura E; Pollak MN
Breast Cancer Res Treat; 2010 Aug; 123(1):271-9. PubMed ID: 20135346
[TBL] [Abstract][Full Text] [Related]
14. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell.
Han G; Gong H; Wang Y; Guo S; Liu K
Cancer Biol Ther; 2015; 16(1):77-87. PubMed ID: 25456211
[TBL] [Abstract][Full Text] [Related]
15. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
[TBL] [Abstract][Full Text] [Related]
16. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
17. Metformin induces G1 cell cycle arrest and inhibits cell proliferation in nasopharyngeal carcinoma cells.
Zhao L; Wen ZH; Jia CH; Li M; Luo SQ; Bai XC
Anat Rec (Hoboken); 2011 Aug; 294(8):1337-43. PubMed ID: 21717584
[TBL] [Abstract][Full Text] [Related]
18. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
Zhang T; Wang X; He D; Jin X; Guo P
Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
[TBL] [Abstract][Full Text] [Related]
19. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
Dowling RJ; Zakikhani M; Fantus IG; Pollak M; Sonenberg N
Cancer Res; 2007 Nov; 67(22):10804-12. PubMed ID: 18006825
[TBL] [Abstract][Full Text] [Related]
20. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
Madera D; Vitale-Cross L; Martin D; Schneider A; Molinolo AA; Gangane N; Carey TE; McHugh JB; Komarck CM; Walline HM; William WN; Seethala RR; Ferris RL; Gutkind JS
Cancer Prev Res (Phila); 2015 Mar; 8(3):197-207. PubMed ID: 25681087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
